BridgeBio Oncology Therapeutics, Inc.

BridgeBio Oncology Therapeutics, Inc. (BBOT) is a clinical-stage biopharmaceutical company focused on developing next-generation small molecule therapeutics targeting RAS-pathway and PI3Kα-driven malignancies — the two most prevalent oncogenes in human tumors. The company's wholly-owned pipeline includes three clinical-stage programs: BBO-8520, an oral KRAS G12C ON/OFF inhibitor for non-small cell lung cancer; BBO-11818, an oral pan-KRAS inhibitor targeting mutant KRAS in both ON and OFF states; and BBO-10203, a novel oral small molecule designed to block the RAS-PI3Kα interaction to inhibit RAS-driven PI3Kα-AKT signaling. BBOT's strategy centers on enabling concurrent dual-pathway suppression of both MAPK and PI3Kα through internal combination strategies across its portfolio, alongside combinations with standard-of-care regimens such as pembrolizumab and cetuximab. The company became publicly traded following a de-SPAC transaction and generates no revenue as a pre-commercial entity. Updated Aug 11, 2026